Decrease in Numbers of Naive and Resting B Cells in HIV-Infected Kenyan Adults Leads to a Proportional Increase in Total and Plasmodium falciparum-Specific Atypical Memory B Cells

The Journal of Immunology : Official Journal of the American Association of Immunologists
Anne E FroschChandy C John

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection is associated with B cell activation and exhaustion, and hypergammaglobulinemia. How these changes influence B cell responses to coinfections such as malaria is poorly understood. To address this, we compared B cell phenotypes and Abs specific for the Plasmodium falciparum vaccine candidate apical membrane Ag-1 (AMA1) in HIV-infected and uninfected adults living in Kenya. Surprisingly, HIV-1 infection was not associated with a difference in serum AMA1-specific Ab levels. HIV-infected individuals had a higher proportion of total atypical and total activated memory B cells (MBCs). Using an AMA1 tetramer to detect AMA1-specific B cells, HIV-infected individuals were also shown to have a higher proportion of AMA1-specific atypical MBCs. However, this proportional increase resulted in large part from a loss in the number of naive and resting MBCs rather than an increase in the number of atypical and activated cells. The loss of resting MBCs and naive B cells was mirrored in a population of cells specific for an Ag to which these individuals were unlikely to have been chronically exposed. Together, the data show that changes in P. falciparum Ag-specific B cell subsets in HIV-infec...Continue Reading

References

Nov 1, 1991·The Journal of Infectious Diseases·B E ShaS A Levin
Aug 11, 1989·JAMA : the Journal of the American Medical Association·P G MiottiM L Clements
Nov 25, 1961·Nature·S COHENS CARRINGTON
Mar 19, 2005·The Journal of Infectious Diseases·Ann M MoormannRosemary Rochford
Apr 6, 2005·The Journal of Infectious Diseases·Angela MalaspinaAnthony S Fauci
Feb 16, 2006·The Journal of Infectious Diseases·Miriam K LauferChristopher V Plowe
Nov 28, 2006·Bulletin of the World Health Organization·A von GottbergKp Klugman
Jan 18, 2008·Clinical and Vaccine Immunology : CVI·Edson G DemboStephen J Rogerson
Mar 26, 2009·Nature Reviews. Immunology·Susan Moir, Anthony S Fauci
Jul 14, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Greta E WeissSusan K Pierce
Sep 16, 2011·The New England Journal of Medicine·Mahamadou A TheraChristopher V Plowe
Oct 1, 2011·Proteomics. Clinical Applications·Obinna N NneduAdam Vigil
Oct 17, 2012·The Journal of Experimental Medicine·Justin J TaylorDaniel L Mueller
Dec 25, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joseph IllingworthFrancis M Ndungu
Jan 16, 2013·The Journal of Experimental Medicine·Matthias F MuellenbeckHedda Wardemann
Jan 15, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Solen KernéisPierre-Yves Boëlle
Mar 8, 2016·PloS One·David S JonesPatrick E Duffy

❮ Previous
Next ❯

Citations

Jun 27, 2018·The American Journal of Tropical Medicine and Hygiene·Anne E P FroschSarah E Cusick
Apr 12, 2019·Parasite Immunology·Ann M MoormannCatherine S Forconi
Dec 15, 2018·European Journal of Immunology·Emily GageRhea N Coler
Apr 20, 2019·Frontiers in Immunology·Ann Ly, Diana S Hansen
Aug 4, 2021·The Journal of Experimental Medicine·Ian C MichelowJonathan D Kurtis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.